Mission
To uncover actionable molecular insights, transforming the odds so that our loved ones can overcome disease.

Our leaders
Meet the team
We bring hope to hard situations. When answers seem impossible, we are committed to finding a way forward.
Explore the lab
Our culture
We care about every molecule and every detail, and we have a passion for discovery. We are intelligent and optimistic, and focus on lighting a way forward to support the future of health.




Our history
A lab like none other
A history of exploration and innovation.
-
20 03
BEAMing (OncoBEAM™) is developed as the first dPCR ctDNA technology (Liquid Biopsy).1
-
20 08
We formed Inostics to be the first Liquid Biopsy provider.
-
20 11
PSS is developed as the first UMI-based NGS Liquid Biopsy technology.2
-
20 12
Our CLIA lab is established to offer the first clinical Liquid Biopsy services for patients in 2013.
-
20 13
Sysmex acquires Inostics to add IVD expertise and global market access capabilities.
-
20 19
PSS is shown to have equivalent sensitivity to OncoBEAM3
-
20 20
BC-SEQ and RAS-RAF-SEQ become Sysmex Inostics’ first CLIA validated PSS testing services.
AML-MRD-SEQ shows promise for recurrence monitoring.4
-
20 21
HPV-SEQ and AML-MRD-SEQ are added to our Baltimore CLIA Lab’s test menu.
QIAGEN® becomes our CDx partner.
HPV-SEQ is proven to detect HPV 16 & 18 in the blood of patients5
NSCLC-SEQ has equivalent sensitivity to OncoBEAM.6
-
20 22
HNSCC-SEQ and AML-SEQ are added to our Test Menu.
HPV-SEQ is used to de-escalate treatment of HPV-driven cancer patients.7
Our careers
Join our team!
If you’re curious, courageous, and bright, we’d love you to consider joining our mission in fighting for a world where diagnosis doesn’t determine life’s potential.
Apply to Sysmex Europe
Contact
We’d love to hear from you!
References
- Dressman 2003 PNAS
- Kinde 2011 PNAS
- Rugo AACR 2019
- Sloane ASH 2020
- Sloane ASH 2020
- Sloane AACR 2021
- Rosenberg BMS 2022